In Vitro Comparison of Fibrinolytic Activity of Plasminogen Activators Using a Thrombelastographic Method: In Vivo Evaluation of the B-Chain-Streptokinase Complex in the Dog Model Using Pre-Titered Doses
- 1 January 1986
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 56 (01) , 071-079
- https://doi.org/10.1055/s-0038-1661606
Abstract
Thrombelastography was used to quantitatively compare the clot-lysing efficiency of 6 different plasminogen activators, using human whole blood, pooled normal plasma, and platelet rich plasma. The activators compared were the B-chain-streptokinase complex, the plasmin-streptokinase complex, the mini-plasmino-gen-streptokinase complex, tissue plasminogen activator, streptokinase, and urokinase. The most efficient activator found was the B-chain-streptokinase complex. This complex was 4.0 times more effective than streptokinase, 3.0 times more effective than the plasmin-streptokinase complex, 1.3 times more effective than the mini-plasminogen-streptokinase complex, 2.3 times more effective than tissue plasminogen activator, and 16.0 times more effective than urokinase. Although there were differences in both the coagulation and fibrinolysis thrombelastographic patterns between plasma and whole blood, the comparative efficiencies of each activator were the same with either plasma or blood The B-chain-streptokinase complex was evaluated as a thrombolytic agent in clot-lysis experiments in the jugular vein in the dog model, using a thrombelastographic method to determine the minimum dose of activator necessary for clot-lysis. With 6 dogs infused locally with 0.25 mg (8000 I.U.) of the plasmin-streptokinase complex, the cumulative clot-lysis was 18.0 ± 3.0% with the first dose, 33.0 ± 2.1% with the second dose, and 55.2 ± 8.6% with the third dose. With 6 dogs infused locally with 0.03 mg (2000 I.U.) of the B-chain-streptokinase complex, the cumulative clot-lysis was 30.6 ± 6.4% with the first dose, 54.4 ± 9.6% with the second dose, and 80.2 ± 9.0% with the third dose.Keywords
This publication has 21 references indexed in Scilit:
- Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolusNature, 1981
- Non surgical coronary artery recanalization in acute transmural myocardial infarction.Circulation, 1981
- Intracoronary thrombolysis in evolving myocardial infarctionAmerican Heart Journal, 1981
- Kinetics of activation of human plasminogen by different activator species at pH 7.4 and 37 degrees C.Journal of Biological Chemistry, 1980
- Steady state kinetics of activation of human and bovine plasminogens by streptokinase and its equimolar complexes with various activated forms of human plasminogen.Journal of Biological Chemistry, 1978
- The dissolution of human cross-linked plasma fibrin clots by the equimolar human plasmin-derived light(B) chain-streptokinase complex. The acceleration of clot lysis by pretreatment of fibrin clots with the light(B) chainThrombosis Research, 1977
- Isolation of a human plasmin-derived, functionally active, light (B) chain capable of forming with streptokinase an equimolar light (B) chain-streptokinase complex with plasminogen activator activity.Journal of Biological Chemistry, 1976
- The Specific Mechanism of Activation of Human Plasminogen to PlasminJournal of Biological Chemistry, 1967
- The Isolation and Characterization of Plasminogen Activators (Urokinase) from Human Urine*Biochemistry, 1966
- DEVELOPMENT OF UROKINASE AS A THROMBOLYTIC AGENT . MAINTENANCE OF A SUSTAINED THROMBOLYTIC STATE IN MAN BY ITS INTRAVENOUS INFUSION1965